Steven Katz compensation by year
TriSalus Life Sciences Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $468,197 | $486,769 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $171,433 |
| Option awards | $85,720 | $591,684 |
| Non-equity incentive | $227,850 | $342,461 |
| Pension and deferred compensation | $0 | $0 |
| All other | $17,379 | $20,658 |
| Total | $799,146 | $1,613,005 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TriSalus Life Sciences, Inc. DEF 14A filed July 19, 2024, accession 0001826667-24-000034, and prior-year filings. Open the filing on EDGAR.
How this page was built: the TriSalus Life Sciences, Inc. filed document, accession 0001826667-24-000034. Every figure is read from that document and cited to the page and table it appears in. Filed July 19, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 12,483 | $106,605 | — |
| Option | 5,558 | — | $12.00 |
| Option | 56,942 | — | $12.00 |
| Option | 21,691 | — | $0.41 |
| Option | 15,659 | — | $2.43 |
| Option | 26,485 | — | $2.43 |
| Option | 63,737 | — | $2.43 |
| Option | 18,276 | — | $10.30 |
| Option | 12,764 | — | $10.30 |
Per the Outstanding Equity Awards at Fiscal Year-End table in TriSalus Life Sciences, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
TriSalus Life Sciences’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Mary Szela | CEO and President | $2,692,830 |
| Steven Katz · this page | Chief Medical Officer | $1,613,005 |
| Sean Murphy | Chief Financial Officer | $1,393,246 |
The full TriSalus Life Sciences compensation record
free company briefThis page is one person within TriSalus Life Sciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TriSalus Life Sciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.